Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5698249 | Clinical Oncology | 2016 | 7 Pages |
Abstract
In a non-trial population of obese patients, dose capping is frequently used. Obese patients receiving uncapped chemotherapy do not experience increased febrile neutropenia rates when compared with uncapped overweight or normal bodyweight patients. Furthermore, dose capping was associated with a trend towards lower rates of febrile neutropenia than in other groups and may indicate relative under-dosing of chemotherapy. This supports international guidelines that state that obese patients should not be dose capped.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
H. Lote, A. Sharp, S. Redana, E. Papadimitraki, M. Capelan, A. Ring,